Board of Directors
Dr. ALAN ROBERTSON - CHAIRMAN
Dr. Robertson has been working with the team at AllVascular since 2017 and has recently been appointed Chairman of the Board of Directors. Alan was the CEO and MD of Pharmaxis Ltd for 14 years. He was responsible for raising more than $350 million in the U.S., Europe and Australia. In that role, he oversaw the development to marketing authorisation a new inhaled dry powder treatment for cystic fibrosis (Bronchitol) and a bronchial challenge test for hyperactive airway disease (Aridol). He also built a drug discovery capability within Pharmaxis and participated in the creation of PXS4728 – now licensed to Boehringer Ingelheim for the treatment of NASH.
Previously, he was the CEO of Promics Ltd (now part of Teva) and developed the first C5a receptor antagonist to patients with rheumatoid arthritis. While head of drug discovery at Kinacia, he invented KN-309, a PI3 kinase inhibitor (subsequently licensed to Astra Zeneca). He is a former member of the scientific advisory board of Xenome Limited, a former Non-Executive Director of Patrys Limited and is a current non-executive director of Advent Ltd. While in the UK, as a Senior Scientist at Wellcome PLC, he invented the anti-migraine drug Zomig.
Prof. RODNEY LANE - NON-EXCUTIVE DIRECTOR
Professor Rodney Lane is Senior Vascular Surgeon at Royal North Shore Hospital. He is also at Sydney Adventist Hospital and Macquarie University Hospital in Sydney. He holds the chair of Vascular Research at Macquarie University. Professor Lane has been involved in numerous vascular research projects over the past 45 years, with the majority focussing on novel Bioengineering approaches. As a curious young vascular surgeon he embarked on his masters of biomedical engineering at the University of NSW. His surgical skills coupled with his new found passion for engineering allowed him to think differently about complex vascular disease. In 2005 Professor Lane developed the IP for the first AVAS Arterial Access System in the hope to improve non-invasive percutaneous control of blood flow to organs and limbs. Essentially his goal with the AVAS® was to provide the same level of control of an organ as in open surgery but through a non-invasive platform.
Professor Lane continues to improve on the AVAS®, ancillary devices and patent portfolio. His highlights include, Doctorate – Venous Valve repairs, Master of Bioengineering – Aortic Endoprosthesis and Master of Surgery – Ultrasonic Transducer Design.
Executive Team
David Lane - Chief Executive Officer
Whilst undergoing his degree at Sydney University, David started working at AllVascular 13 years ago. During his tenure he has gained experience in all facets of the company including clinical trials, manufacturing, intellectual property (patents), regulatory affairs, reimbursement, sales and marketing. David has played an integral role in developing and executing AllVascular’s business plan and building the management and executive teams to date. His proven success in winning grants (NSW Medical Device Fund 2015, 2020), raising capital and his directive to bring the AVAS® manufacturing in-house have been pivotal to AllVascular’s recent growth
Rick Stark - International Business Development Director
Based out of the United States, Rick joins the AllVascular team and brings over 25 years of experience in the medical device industry with a focus on interventional oncology and ablation devices. Rick spent 10 years at AngioDynamics in New York as General Manager and Senior Vice President building their Oncology/Surgery Global Business Unit.
Rick currently serves as a Board member at Sanarus and is an advisor to companies such as Embolex Inc, who develop microcatheters for arterial embolization procedures.
As International Business Development Director at AllVascular, Rick has the responsibility of building distribution networks in the United States and Europe for the AVAS® device.